Skip to main
HOWL
HOWL logo

Werewolf Therapeutics (HOWL) Stock Forecast & Price Target

Werewolf Therapeutics (HOWL) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Werewolf Therapeutics Inc. is positioned favorably due to its innovative PREDATOR platform, which allows for the development of novel therapeutics aimed at enhancing the body's immune response to cancer. The company has shown potential for significant growth, as evidenced by its focus on conditionally activated INDUKINE molecules that selectively target the tumor microenvironment, thus addressing the limitations of traditional therapies. Financial metrics indicate a positive trajectory, as reflected in the enhanced guidance for Core Funds From Operations (Core FFO), which demonstrates strong demand and operational performance alongside modest expense growth.

Bears say

The analysis indicates a negative outlook for Werewolf Therapeutics, primarily due to the downward revision in full-year same-store revenue growth forecasts, reflecting weakened operational performance. The company reported a decline in year-over-year revenues of 30 basis points alongside a 3.8% increase in expenses, resulting in a notable decrease of 2.6% in net operating income. Furthermore, the average effective rental rate also experienced a 50 basis point decline, signaling challenges in maintaining revenue growth amidst competitive leasing conditions.

Werewolf Therapeutics (HOWL) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Werewolf Therapeutics (HOWL) Forecast

Analysts have given Werewolf Therapeutics (HOWL) a Buy based on their latest research and market trends.

According to 4 analysts, Werewolf Therapeutics (HOWL) has a Buy consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Werewolf Therapeutics (HOWL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.